Revolution Medicines (RVMD) Stock Jumps 38% Following Breakthrough Pancreatic Cancer Data

Key Highlights RVMD shares climbed approximately 38–40% during premarket hours Monday, reaching roughly $134 per share Daraxonrasib Phase 3 data revealed median overall survival of 13.2 months compared to 6.7 months with conventional chemotherapy This oral medication, taken daily, addresses RAS mutations present in more than 90% of pancreatic cancer patients The company intends to submit a New Drug Application to the FDA utilizing a priority voucher Analysts at RBC Capital Markets project the drug’s market potential exceeds $10 billion Revolution Medicines delivered one of Monday’s most dramatic premarket performances following the release of Phase 3 clinical trial data for daraxonrasib that significantly exceeded market expectations. Revolution Medicines, Inc., RVMD The oral medication, administered once daily, achieved median overall survival that was nearly double that of conventional chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma who had received prior treatment — 13.2 months compared to 6.7 months. These outcomes surpassed the benchmarks established by Wall Street analysts. Leonid Timashev from RBC Capital Markets had previously identified 11–12 months as the critical threshold for overall survival that investors were monitoring prior to the data release. Daraxonrasib works by targeting RAS mutations, genetic alterations found in over 90% of pancreatic cancer diagnoses and recognized as key contributors to cancer progression. The clinical study encompassed patients with diverse RAS mutation types, including some participants without detectable RAS mutations. Pancreatic cancer remains among the deadliest malignancies, with a five-year survival rate hovering around just 13%. Therapeutic alternatives for patients who have progressed beyond initial treatment remain severely limited. “For patients with metastatic pancreatic cancer, new treatment options are urgently needed to increase survival time and improve quality of life,” said Bri...